Ang immune checkpoint inhibitors ay isang klase ng mga gamot na lumalaban sa immune system ng katawan upang labanan ang mga cancerous cells. Gayunpaman, karamihan sa mga pasyente ay hindi tumutugon sa mga therapy na ito. May mas bagong klase ng gamot na nagta-target ng dalawang protina na kasangkot sa pagsugpo sa immune response ng katawan laban sa mga tumor.
Phase I of clinical trials has shown some exciting results, which were conducted in 19 patients suffering from kanser with the molecule M7824. These researchers are also undertaking trials with those suffering from pancreatic cancer at ang mga nahawaan ng HPV.
There are many other trials and experiments being taken to treat and gamutin ang cancer more effectively in different research institutes. This drug with a dual approach will be a boon in the paggamot ng cancer, as with a single molecule, multiple therapies are included.